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Background
The debate on whether or not breast cancer is in the
tumor spectrum for Lynch syndrome produces a con-
undrum for healthcare providers. The classic tumor
spectrum for Lynch Syndrome (LS) includes colon,
endometrial, ovarian, stomach, small intestine, hepato-
biliary, urinary tract and brain/central nervous system
cancers. Muir-Torre Syndrome (MTS) is a variant of
LS that is associated with additional skin lesions
including sebaceous gland tumors and keratoacantho-
mas. MTS was observed in 28% of LS families when
assessing for MTS skin lesions [1]. It has also been
reported that 10-14% of individuals with MTS present
initially with breast cancer [2,3]. An extensive study
published in 2002 excluded breast cancer as part of
the tumor spectrum associated with LS [4]. However,
more recently it was reported that DNA mismatch
repair (MMR) gene deficiencies were identified in 51%
of breast cancers arising in MMR mutation carriers
[5]. Another study reported a male with an MLH1
mutation who had both colon and breast cancer. The
breast cancer exhibited somatic reduction to homozyg-
o s i t yf o rt h eM L H 1m u t a t i o n[ 6 ] .H e r ew er e p o r tt w o
unrelated families in which the proband has a germline
MMR gene mutation and bilateral breast cancer, and
one family in which the proband had ovarian and renal
cancer and her daughter, maternal aunt and cousin
had breast cancer at age 47, 59, and 48 respectively.
This raises the question are these breast cancers asso-
ciated with the MMR mutations or a breast cancer
susceptibility gene and what testing should be offered?
Methods
Three families underwent genetic counseling and testing
through the Familial Cancer Risk Assessment Program
and were found to have mutations in an MMR gene.
All three families were then offered BRCA1/BRCA2 test-
ing based on a personal and/or family history suggestive
of hereditary breast and ovarian cancer. Informed con-
sent was obtained and the proband underwent BRCA1/
BRCA2 testing.
Results
All three probands underwent BRCA1/BRCA2 DNA
sequencing and one proband had large rearrangement
analysis performed. All three probands were negative for
alterations in BRCA1/BRCA2 genes.
Conclusion
Our findings indicate that breast cancer is part of the
spectrum of tumors in LS families in which the breast
cancer segregates with the other LS associated tumors.
Additional hereditary breast cancer gene testing may not
be warranted in these circumstances. A future research
goal is to perform IHC on the breast tumors from these
families to determine if they show loss of expression of
the MMR gene that is known to be altered.
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